Forty-One Approved Addiction Drugs, and Not One for Meth or Cannabis: What the Biggest Medication Review Yet Actually Found

Nobody in recovery needs a journal to tell them that a medicine exists for some substances and not for others. They have lived the difference. What a new paper does is count it. In CNS Drugs, Danovitch and colleagues reviewed 16 systematic reviews covering 371 trials, and the shape of the evidence is the story: it is lopsided in a way that tracks what has been studied, not just what works.

The medicine map for addiction has a blank spot exactly where methamphetamine and cannabis sit, and the blank is a research choice, not a law of nature.

First, what kind of study this is. An umbrella review is a review of reviews: instead of pooling raw trial data, the authors gather published systematic reviews and the completed late-stage randomized trials, and ask what the pile adds up to. That makes it a good map and a poor microscope. It can tell you where evidence is deep or shallow. It cannot tell you how a specific person will respond, and it inherits the flaws of the reviews underneath it. MentalHealthDaily’s summary reports that the authors identified 41 approved medications (25 distinct molecules) as of January 1, 2026.

What the strong evidence looks like

Tobacco has the deepest bench. The review counted 223 tobacco trials, and for varenicline (the quit-smoking pill sold as Chantix) it reports a risk ratio of 2.32 across 41 trials and 17,395 smokers. In plain terms: people on varenicline were roughly twice as likely to quit as people on placebo. Opioids sit second in strength, with 49 trials. The review reports that methadone kept people in treatment longer than buprenorphine, with a retention ratio of 0.76 for buprenorphine, or about 24% less retention. Retention is not the same as being well, and both medications are recognized by the FDA as first-line tools. But a program that sees a client stalling on buprenorphine now has a published reason to ask about methadone rather than treating the stall as a personal failure.

Alcohol is the middle case: 86 trials, modest benefit. As reported, the best alcohol drugs lowered relapse risk by roughly 7% to 17%. We could not confirm from the summary whether that is absolute or relative risk, which changes how big it feels, so read the paper before quoting the figure.

What the blank looks like

One phase 3 trial for stimulants. Zero for cannabis. That one stimulant trial is ADAPT-2, in methamphetamine use disorder, where 13.6% of people on the naltrexone-bupropion combination responded versus 2.5% on placebo. It is an encouraging signal and it is also a single trial, which is why no drug is approved. Nothing is approved in the review’s scope for cannabis, cocaine, methamphetamine or other stimulants, hallucinogens, inhalants or caffeine.

If you use a stimulant, this is the part that has been true your whole time in treatment: you were told to white-knuckle a thing nobody had bothered to build a pill for. That is not you failing a medication. There is no medication to fail. The review’s authors are careful about their own limits, writing that “missing is not the same as failed” and noting that six approved drugs lacked a qualifying review at all. Absence of evidence here mostly means absence of trials.

What to do with it this week

If you run or staff a program, three moves. At the next case conference, pull any opioid client who has stalled on buprenorphine and ask whether methadone has been offered, and what the access barrier is. Check that every client who smokes has been offered a quit medication, because tobacco is where the evidence is strongest and where treatment programs most often look away. And for stimulant clients, stop describing the options as “counseling or nothing”: behavioral approaches such as contingency management (small rewards for stimulant-free tests) are the tools actually available, and the SAMHSA treatment options page is a place to start a referral conversation.

Check that every client who smokes has been offered a quit medication, because tobacco is where the evidence is strongest and where treatment programs most often look away.

The gap matters beyond pharmacology. By SAMHSA survey figures summarized by Acuity News, 84% of the 47.2 million Americans who needed treatment did not receive it. The people with the fewest tools are also among those least likely to be reached at all.

The takeaway is not despair. It is a funding request with a number on it: one trial for stimulants, none for cannabis. That is how many chances we have given people to find out.